

Birth incidence and prevalence of tumor-prone syndromes in a  
genetic register service

American Journal of Medical Genetics, Part A  
152A, 327-332

DOI: [10.1002/ajmg.a.33139](https://doi.org/10.1002/ajmg.a.33139)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. <i>Annals of Neurology</i> , 2007, 61, 189-198.	2.8	531
2	Meningiomas and neurofibromatosis. <i>Journal of Neuro-Oncology</i> , 2010, 99, 341-347.	1.4	113
3	The neurofibromatoses. <i>Practical Neurology</i> , 2010, 10, 82-93.	0.5	116
4	Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. <i>European Journal of Human Genetics</i> , 2011, 19, 1187-1191.	1.4	161
5	Epidemiology of Inherited Colon Cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2011, 22, 77-81.	0.2	0
6	Medical management of neurofibromatosis. <i>Paediatrics and Child Health (United Kingdom)</i> , 2011, 21, 459-465.	0.2	1
8	Ovarian preservation in a young patient with Gorlin syndrome and multiple bilateral ovarian masses. <i>Fertility and Sterility</i> , 2011, 96, e47-e50.	0.5	13
9	Malignant peripheral nerve sheath tumours in NF1: Improved survival in women and in recent years. <i>European Journal of Cancer</i> , 2011, 47, 2723-2728.	1.3	33
10	Voice Characteristics in Adults With Neurofibromatosis Type 1. <i>Journal of Voice</i> , 2011, 25, 759-764.	0.6	4
11	Syndromes Associated with Intracranial Tumours: A Paediatric Neurosurgeon's Perspective. , 2011, , .		0
12	Middle Fossa Decompression for Hearing Preservation. <i>Otology and Neurotology</i> , 2011, 32, 1017-1024.	0.7	33
13	An 8.9 year old girl with autism and Gorlin syndrome. <i>European Journal of Paediatric Neurology</i> , 2011, 15, 268-270.	0.7	6
14	Neurofibromatosis Type 2 (NF2). , 2011, , 47-70.		3
15	Features of basal cell carcinomas in basal cell nevus syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2011, 155, 2098-2104.	0.7	21
16	Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2094-2103.	1.9	31
17	Basal Cell Carcinomas in Gorlin Syndrome: A Review of 202 Patients. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-6.	0.5	99
18	The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2012, 73, 104-111.	0.4	29
19	Alternative splicing of the neurofibromatosis type1 pre-mRNA. <i>Bioscience Reports</i> , 2012, 32, 131-138.	1.1	41

#	ARTICLE	IF	CITATIONS
20	Surgery for neurofibromatosis 2. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012, 20, 347-352.	0.8	10
21	Basal cell carcinoma " molecular biology and potential new therapies. <i>Journal of Clinical Investigation</i> , 2012, 122, 455-463.	3.9	122
22	Tumors of Central and Peripheral Nervous System Associated with Inherited Genetic Syndromes. <i>Pediatric Neurosurgery</i> , 2012, 48, 271-285.	0.4	27
23	Bone mineral density in children and young adults with neurofibromatosis type 1. <i>Endocrine-Related Cancer</i> , 2012, 19, 817-825.	1.6	16
24	Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. <i>Neuro-Oncology</i> , 2012, 14, 1090-1096.	0.6	72
25	Genetic skin diseases predisposing to basal cell carcinoma. <i>European Journal of Dermatology</i> , 2012, 22, 299-309.	0.3	71
26	Merlin: The wizard requires protein stability to function as a tumor suppressor. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 400-406.	3.3	24
27	Increased risk of breast cancer in women with NF1. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 3056-3060.	0.7	94
28	Voice-Related Quality of Life in Adults With Neurofibromatosis Type 1. <i>Journal of Voice</i> , 2012, 26, e57-e62.	0.6	7
29	Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature. <i>BMC Medical Genetics</i> , 2012, 13, 19.	2.1	37
30	Malignant peripheral nerve sheath tumours in inherited disease. <i>Clinical Sarcoma Research</i> , 2012, 2, 17.	2.3	93
31	Neurofibromatoses. <i>Advances in Experimental Medicine and Biology</i> , 2012, 724, 266-277.	0.8	27
32	The Germline Mutational Spectrum in Neurofibromatosis Type 1 and Genotype-Phenotype Correlations. , 2012, , 115-134.		6
33	Novel PTCH1 Mutations in Patients with Keratocystic Odontogenic Tumors Screened for Nevoid Basal Cell Carcinoma (NBCC) Syndrome. <i>PLoS ONE</i> , 2012, 7, e43827.	1.1	20
34	Uncommon Ocular Manifestations of Neurofibromatosis: Case Report and Review. <i>Journal of Korean Ophthalmological Society</i> , 2012, 53, 1200.	0.0	0
35	Life expectancy in hereditary cancer predisposing diseases: an observational study. <i>Journal of Medical Genetics</i> , 2012, 49, 264-269.	1.5	121
36	Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. <i>Neuro-Oncology</i> , 2012, 14, 1163-1170.	0.6	148
37	Biallelic inactivation of <i>NF1</i> in a sporadic plexiform neurofibroma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 852-857.	1.5	22

#	ARTICLE	IF	CITATIONS
38	Neurofibromatosis 2. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 315-332.	0.5	31
39	A benign form of congenital anterolateral bowing of the tibia associated with ipsilateral polydactyly of the hallux: Case report and literature review. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 1742-1749.	0.7	6
41	Is <i>PATCHED</i> an important candidate gene for neural tube defects? Cranial and thoracic neural tube defects in a family with Gorlin syndrome: a case report. <i>Clinical Genetics</i> , 2012, 82, 71-76.	1.0	11
42	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 24-41.	0.7	101
43	Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes. <i>Acta Neuropathologica</i> , 2012, 123, 349-367.	3.9	74
44	Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. <i>Journal of Neuro-Oncology</i> , 2013, 114, 257-262.	1.4	81
45	Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome. <i>Genetics in Medicine</i> , 2013, 15, 79-83.	1.1	43
46	The Phakomatoses. , 2013, , 1-45.		1
47	Neurofibromatosis type 2 (NF2). <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 115, 957-967.	1.0	66
49	Advances in the treatment of neurofibromatosis-associated tumours. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 616-624.	12.5	88
50	Social functioning in adults with neurofibromatosis type 1. <i>Research in Developmental Disabilities</i> , 2013, 34, 3393-3399.	1.2	29
51	Development of an international internet-based neurofibromatosis Type 1 Patient registry. <i>Contemporary Clinical Trials</i> , 2013, 34, 305-311.	0.8	30
52	Multiple tumor types including leiomyoma and Wilms tumor in a patient with Gorlin syndrome due to 9q22.3 microdeletion encompassing the <i>PTCH1</i> and <i>FANCA</i> loci. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 2894-2901.	0.7	17
53	Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. <i>Developmental Medicine and Child Neurology</i> , 2013, 55, 111-125.	1.1	167
54	Clinical manifestations and treatment for keratocystic odontogenic tumors associated with nevoid basal cell carcinoma syndrome: a study in 25 Japanese patients. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 275-280.	1.4	16
55	Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials. <i>Journal of Neurology</i> , 2013, 260, 214-220.	1.8	26
56	Neurofibromatosis Type 1 and Autism Spectrum Disorder. <i>Pediatrics</i> , 2013, 132, e1642-e1648.	1.0	145
57	Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 1076-1083.	4.9	113

#	ARTICLE	IF	CITATIONS
58	Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. <i>Developmental Medicine and Child Neurology</i> , 2013, 55, 139-145.	1.1	149
59	Modification of risk for cancer as a coincidental finding in DNA array investigation. <i>Clinical Genetics</i> , 2013, 83, 284-287.	1.0	1
60	Optimizing biologically targeted clinical trials for neurofibromatosis. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 443-462.	1.9	77
61	Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation. <i>European Journal of Human Genetics</i> , 2013, 21, 535-539.	1.4	27
62	Genetic and Functional Studies Implicate Synaptic Overgrowth and Ring Gland cAMP/PKA Signaling Defects in the <i>Drosophila melanogaster</i> Neurofibromatosis-1 Growth Deficiency. <i>PLoS Genetics</i> , 2013, 9, e1003958.	1.5	42
63	Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. <i>British Journal of Cancer</i> , 2013, 108, 193-198.	2.9	168
64	Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients. <i>Neurosurgery</i> , 2013, 72, 907-914.	0.6	38
65	Optical Coherence Tomography in the Diagnosis of Optic Pathway Gliomas. , 2013, 54, 8112.		41
66	Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. The Application of <i>Clinical Genetics</i> , 2013, 6, 53.	1.4	16
67	Autres affections. , 2013, , 803-827.		1
68	The Epidemiology of Paediatric Brain Cancer – Descriptive Epidemiology and Risk Factors. , 2013, , .		2
69	Molecular Biology of Basal and Squamous Cell Carcinomas. , 2014, 810, 234-252.		24
70	Current Concepts in Management of Vestibular Schwannomas in Neurofibromatosis Type 2. <i>Current Otorhinolaryngology Reports</i> , 2014, 2, 248-255.	0.2	0
71	Ultrasound as a Diagnostic Aid in Identifying Neurofibromas. <i>Pediatric Dermatology</i> , 2014, 31, 535-537.	0.5	17
72	Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. <i>Developmental Medicine and Child Neurology</i> , 2014, 56, 468-474.	1.1	39
73	Consensus recommendations for the treatment of basal cell carcinomas in <sc>G</sc> orlin syndrome with topical methylaminolaevulinate-photodynamic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 626-632.	1.3	44
74	The Genetics of Vestibular Schwannoma. <i>Current Otorhinolaryngology Reports</i> , 2014, 2, 226-234.	0.2	8
75	Patient With Gorlin Syndrome and Metastatic Basal Cell Carcinoma Refractory to Smoothened Inhibitors. <i>JAMA Dermatology</i> , 2014, 150, 877.	2.0	12

#	ARTICLE	IF	CITATIONS
77	Characterizing the microstructural basis of "unidentified bright objects" in neurofibromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis. <i>NeuroImage: Clinical</i> , 2014, 4, 649-658.	1.4	92
78	Characterization of early onset neurofibromatosis type 2. <i>Brain and Development</i> , 2014, 36, 148-152.	0.6	22
79	Familial syndromes associated with intracranial tumours: a review. <i>Child's Nervous System</i> , 2014, 30, 47-64.	0.6	24
80	The genetic and neuroanatomical basis of social dysfunction: Lessons from neurofibromatosis type 1. <i>Human Brain Mapping</i> , 2014, 35, 2372-2382.	1.9	30
81	Longitudinal assessment of cognition and T2-hyperintensities in NF1: An 18-year study. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 661-665.	0.7	41
82	The mutational spectrum of the NF1 gene in neurofibromatosis type I patients from UAE. <i>Child's Nervous System</i> , 2014, 30, 1183-1189.	0.6	8
83	Neurodermatology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 121, 1561-1594.	1.0	9
84	Gorlin syndrome (nevoid basal cell carcinoma syndrome): Update and literature review. <i>Pediatrics International</i> , 2014, 56, 667-674.	0.2	80
85	Deficient motor timing in children with neurofibromatosis type 1. <i>Research in Developmental Disabilities</i> , 2014, 35, 3131-3138.	1.2	8
86	mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. <i>Neuro-Oncology</i> , 2014, 16, 493-504.	0.6	67
87	Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. <i>Journal of Neurology</i> , 2014, 261, 963-969.	1.8	39
88	Angiosarcoma arising in schwannoma of cerebellopontine angle and later associating with meningioma in a patient with neurofibromatosis type 2. <i>Brain Tumor Pathology</i> , 2014, 31, 293-298.	1.1	9
89	Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. <i>European Journal of Epidemiology</i> , 2014, 29, 293-301.	2.5	40
90	Cribiform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP. <i>Familial Cancer</i> , 2014, 13, 547-551.	0.9	22
91	The pathology of colorectal polyps and cancers (including biopsy). <i>Surgery</i> , 2014, 32, 165-171.	0.1	2
92	Neurofibromatosis Type 2 and Its Head and Neck Manifestations: Literature Review and Population Study in the Community of Cantabria and the Province of Las Palmas. <i>Acta Otorrinolaringologica (English Edition)</i> , 2014, 65, 148-156.	0.1	2
94	Primary culture of human Schwann and schwannoma cells: Improved and simplified protocol. <i>Hearing Research</i> , 2014, 315, 25-33.	0.9	37
95	Systemic therapy in neurofibromatosis type 2. <i>Cancer Treatment Reviews</i> , 2014, 40, 857-861.	3.4	33

#	ARTICLE	IF	CITATIONS
96	Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients. <i>Otology and Neurotology</i> , 2014, 35, e50-e56.	0.7	60
97	Neurofibromatosis type 1. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 132, 75-86.	1.0	137
98	Von Hippel-Lindau disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 132, 139-156.	1.0	136
99	Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 72-80.	1.1	86
100	Management of an expansile orbital mass: Plexiform neurofibroma decompression by orbitozygomatic approach. <i>Laryngoscope</i> , 2015, 125, 2457-2460.	1.1	3
101	Cognition in children with neurofibromatosis type 1: data from a population-based study. <i>Developmental Medicine and Child Neurology</i> , 2015, 57, 645-651.	1.1	43
102	In Silico Analysis of NF2 Gene Missense Mutations in Neurofibromatosis Type 2. <i>Otology and Neurotology</i> , 2015, 36, 908-914.	0.7	13
103	Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in <i>BRCA1</i> . <i>Journal of Breast Cancer</i> , 2015, 18, 97.	0.8	15
104	In Vivo Detection of Choroidal Abnormalities Related to NF1: Feasibility and Comparison With Standard NIH Diagnostic Criteria in Pediatric Patients. , 2015, 56, 6036.		46
105	Basal cell nevus syndrome or Gorlin syndrome. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 132, 119-128.	1.0	36
106	Neurofibromatosis type 2. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 132, 87-96.	1.0	45
107	Association between Neurofibromatosis Type 1 and Breast Cancer: A Report of Two Cases with a Review of the Literature. <i>Case Reports in Medicine</i> , 2015, 2015, 1-6.	0.3	8
108	Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome. <i>European Journal of Human Genetics</i> , 2015, 23, 708-710.	1.4	10
109	Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety. <i>International Journal of Dermatology</i> , 2015, 54, 370-374.	0.5	16
110	Incidence and Mortality of Neurofibromatosis: A Total Population Study in Finland. <i>Journal of Investigative Dermatology</i> , 2015, 135, 904-906.	0.3	189
111	Autism Spectrum Disorder Profile in Neurofibromatosis Type I. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 1649-1657.	1.7	54
112	Neurofibromatosis Type 2. <i>Otolaryngologic Clinics of North America</i> , 2015, 48, 443-460.	0.5	45
113	Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. <i>Journal of Medical Genetics</i> , 2015, 52, 557-562.	1.5	40

#	ARTICLE	IF	CITATIONS
114	Advances in Molecular Diagnosis of Neurofibromatosis Type 1. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 234-239.	1.0	29
115	Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. <i>Journal of Neuro-Oncology</i> , 2015, 122, 219-228.	1.4	47
116	Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. <i>Journal of Neuro-Oncology</i> , 2015, 122, 313-320.	1.4	87
117	Biome depletion in conjunction with evolutionary mismatches could play a role in the etiology of neurofibromatosis 1. <i>Medical Hypotheses</i> , 2015, 84, 305-314.	0.8	1
118	Bilateral vestibular schwannomas in older patients: NF2 or chance?. <i>Journal of Medical Genetics</i> , 2015, 52, 422-424.	1.5	33
119	Vestibular Schwannoma Excision in Sporadic versus Neurofibromatosis Type 2 Populations. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 153, 822-831.	1.1	23
120	Pathogenesis and management of type 2 neurofibromatosis. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 281-292.	0.5	0
121	Discovery of Rare Mutations in Autism: Elucidating Neurodevelopmental Mechanisms. <i>Neurotherapeutics</i> , 2015, 12, 553-571.	2.1	21
122	A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. <i>Nature Reviews Cancer</i> , 2015, 15, 290-301.	12.8	348
123	The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults. <i>Journal of Genetic Counseling</i> , 2015, 24, 931-944.	0.9	33
124	Neurofibromatosis-related tumors. <i>Current Opinion in Pediatrics</i> , 2015, 27, 26-33.	1.0	64
125	Developmental Trajectories of Young Children with Neurofibromatosis Type 1: A Longitudinal Study from 21 to 40 Months of Age. <i>Journal of Pediatrics</i> , 2015, 166, 1006-1012.e1.	0.9	18
126	Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. <i>Journal of Medical Genetics</i> , 2015, 52, 699-705.	1.5	78
127	The genetic basis of intradural spinal tumors and its impact on clinical treatment. <i>Neurosurgical Focus</i> , 2015, 39, E3.	1.0	43
128	A Novel von Hippel Lindau Gene Intronic Variant and Its Reclassification from VUS to Pathogenic: the Impact on a Large Family. <i>Journal of Genetic Counseling</i> , 2015, 24, 882-889.	0.9	9
129	3D Volumetric Measurement of Neurofibromatosis Type 2-Associated Meningiomas: Association Between Tumor Location and Growth Rate. <i>World Neurosurgery</i> , 2015, 84, 1062-1069.	0.7	19
130	Tumors of the neural crest: Common themes in development and cancer. <i>Developmental Dynamics</i> , 2015, 244, 311-322.	0.8	91
131	Spectral-Domain Optical Coherence Tomography Findings in Neurofibromatosis Type 2. , 2016, 57, OCT262.		13



#	ARTICLE	IF	CITATIONS
132	Endocrine Hypertension. , 2016, , 556-588.		8
133	Uptake of health monitoring and disease self-management in Australian adults with neurofibromatosis type 1: strategies to improve care. <i>Clinical Genetics</i> , 2016, 89, 385-391.	1.0	6
134	Comment on: <i>DICER1</i> Negative Pleuropulmonary Blastoma in a Patient With Selective IgA Deficiency. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1869-1870.	0.8	2
135	Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration. <i>Laryngoscope</i> , 2016, 126, 2358-2362.	1.1	15
136	Executive functioning deficits in children with neurofibromatosis type 1: The influence of intellectual and social functioning. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 348-362.	1.1	37
137	A 40-Year-Old Woman With Back Pain. <i>Chest</i> , 2016, 150, e159-e165.	0.4	2
138	Confounding of the association between radiation exposure from CT scans and risk of leukemia and brain tumors by cancer susceptibility syndromes. <i>Journal of Radiological Protection</i> , 2016, 36, 953-974.	0.6	25
139	A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK/PI3K induced malignant growth. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 15-28.	1.2	58
140	Mice with missense and nonsense <i>NF1</i> mutations display divergent phenotypes compared to <i>NF1</i> patients. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 759-67.	1.2	23
141	Comprehensive RNA Analysis of the <i>NF1</i> Gene in Classically Affected <i>NF1</i> Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only. <i>EBioMedicine</i> , 2016, 7, 212-220.	2.7	69
142	Diagnosis and Management of Hereditary Sarcoma. <i>Recent Results in Cancer Research</i> , 2016, 205, 169-189.	1.8	4
143	Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome Cohort. <i>Dermatology</i> , 2016, 232, 285-292.	0.9	16
144	What Is the Malignancy Risk in Neurofibromatosis Type 1?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1967-1969.	0.8	8
145	Phonics Training Improves Reading in Children with Neurofibromatosis Type 1: A Prospective Intervention Trial. <i>Journal of Pediatrics</i> , 2016, 177, 219-226.e2.	0.9	10
146	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
147	Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib. <i>Cancer Biology and Therapy</i> , 2016, 17, 1010-1016.	1.5	19
148	Skin manifestations of growth hormone-induced diseases. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 259-267.	2.6	37
149	Neurovascular manifestations of connective-tissue diseases: A review. <i>Interventional Neuroradiology</i> , 2016, 22, 624-637.	0.7	69

#	ARTICLE	IF	CITATIONS
150	The effect of parental age on the presence of de novo mutations â€“ Lessons from neurofibromatosis type I. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2016, 4, 480-486.	0.6	21
151	Immortalization of human normal and NF1 neurofibroma Schwann cells. <i>Laboratory Investigation</i> , 2016, 96, 1105-1115.	1.7	60
152	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. <i>Neurology</i> , 2016, 87, 2575-2584.	1.5	76
153	Theory of mind in children with Neurofibromatosis Type 1.. <i>Neuropsychology</i> , 2016, 30, 439-448.	1.0	27
154	Sex bias in autism spectrum disorder in neurofibromatosis type 1. <i>Journal of Neurodevelopmental Disorders</i> , 2016, 8, 26.	1.5	24
155	Correlation Between Aspirin Intake and Reduced Growth of Human Vestibular Schwannoma. <i>Otology and Neurotology</i> , 2016, 37, 1428-1434.	0.7	46
156	Auditory Brainstem Implantation in Chinese Patients With Neurofibromatosis Type II. <i>Otology and Neurotology</i> , 2016, 37, 956-962.	0.7	6
157	Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity. <i>Pediatric Blood and Cancer</i> , 2016, 63, 418-427.	0.8	32
158	National survey of patients with Gorlin syndrome highlights poor awareness, multiple treatments and profound psychosocial impact of disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 371-373.	1.3	3
159	Neuropsychological evaluation and parental assessment of behavioral and motor difficulties in children with neurofibromatosis type 1. <i>Research in Developmental Disabilities</i> , 2016, 48, 220-230.	1.2	14
160	Recent developments in brain tumor predisposing syndromes. <i>Acta OncolÃ³gica</i> , 2016, 55, 401-411.	0.8	31
161	A randomized placeboâ€“controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 266-279.	1.7	44
162	The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes. <i>Human Mutation</i> , 2016, 37, 250-256.	1.1	65
163	Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. <i>Neuro-Oncology</i> , 2016, 18, 624-638.	0.6	94
164	Concurrent Ulcerative Colitis and Neurofibromatosis Type 1: The Question of a Common Pathway. <i>Pediatrics</i> , 2016, 137, e20150973.	1.0	8
165	Plexiform Neurofibroma. <i>Medicine (United States)</i> , 2016, 95, e2663.	0.4	37
166	Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1. <i>Stroke</i> , 2016, 47, 60-65.	1.0	59
167	Confounding of the Association between Radiation Exposure from CT Scans and Risk of Leukemia and Brain Tumors by Cancer Susceptibility Syndromes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 114-126.	1.1	5

#	ARTICLE	IF	CITATIONS
168	Motor impairment in children with Neurofibromatosis type 1: Effect of the comorbidity with language disorders. <i>Brain and Development</i> , 2016, 38, 181-187.	0.6	22
169	High prevalence of elevated blood pressure among children with neurofibromatosis type 1. <i>Pediatric Nephrology</i> , 2016, 31, 131-136.	0.9	19
170	Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1. <i>Neurology</i> , 2016, 86, 154-160.	1.5	26
171	Neurocutaneous Syndromes and Brain Tumors. <i>Journal of Child Neurology</i> , 2016, 31, 1399-1411.	0.7	15
173	Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark. <i>European Journal of Human Genetics</i> , 2017, 25, 301-307.	1.4	45
174	Aneurysms in neurofibromatosis type 2: Evidence for vasculopathy?. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1562-1565.	0.7	5
176	Epidemiology and Etiology of Childhood ALL. , 2017, , 1-27.		4
178	Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. <i>Clinical Cancer Research</i> , 2017, 23, e46-e53.	3.2	133
179	Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. <i>Clinical Cancer Research</i> , 2017, 23, e54-e61.	3.2	76
180	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, e62-e67.	3.2	139
181	Visuoperceptual processing in children with neurofibromatosis type 1: True deficit or artefact?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 342-358.	1.1	13
182	Development of emotional and behavioral problems in neurofibromatosis type 1 during young childhood. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 2373-2380.	0.7	7
183	First evidence of genotype-phenotype correlations in Gorlin syndrome. <i>Journal of Medical Genetics</i> , 2017, 54, 530-536.	1.5	56
184	Motor problems in children with neurofibromatosis type 1. <i>Journal of Neurodevelopmental Disorders</i> , 2017, 9, 19.	1.5	22
185	Cranial irradiation in childhood mimicking neurofibromatosis type II. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1635-1639.	0.7	2
186	The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study. <i>Cortex</i> , 2017, 93, 1-11.	1.1	14
187	Predicting neurofibromatosis type 1 risk among children with isolated café-au-lait macules. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1077-1083.e3.	0.6	28
188	Molecular Genetics of Pheochromocytoma and Paraganglioma. , 2017, , 15-45.		0

#	ARTICLE	IF	CITATIONS
189	Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome. <i>JAMA Dermatology</i> , 2017, 153, 189.	2.0	20
190	Genetic Severity Score predicts clinical phenotype in NF2. <i>Journal of Medical Genetics</i> , 2017, 54, 657-664.	1.5	87
191	The prevalence of <i>DICER1</i> pathogenic variation in population databases. <i>International Journal of Cancer</i> , 2017, 141, 2030-2036.	2.3	75
192	Endovascular management of renal artery aneurysms induced by neurofibromatosis type 1. <i>Medicine (United States)</i> , 2017, 96, e8858.	0.4	3
193	Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors. <i>Current Osteoporosis Reports</i> , 2017, 15, 239-246.	1.5	33
194	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. <i>Clinical Cancer Research</i> , 2017, 23, e107-e114.	3.2	91
195	Nevoid basal cell carcinoma syndrome caused by splicing mutations in the <i>PTCH1</i> gene. <i>Familial Cancer</i> , 2017, 16, 131-138.	0.9	13
196	Brain Tumors—Epidemiology. , 2017, , 279-290.		1
197	Choroidal abnormalities in café-au-lait syndromes: a new differential diagnostic tool?. <i>Clinical Genetics</i> , 2017, 91, 529-535.	1.0	20
198	Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 79-87.	0.7	27
199	Auditory brainstem implant program development. <i>Laryngoscope</i> , 2017, 127, 1909-1915.	1.1	7
200	A multidisciplinary approach to the successful management of Gorlin syndrome. <i>Journal of Surgical Case Reports</i> , 2017, 2017, rjw224.	0.2	1
201	Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. <i>Frontiers in Pediatrics</i> , 2017, 5, 227.	0.9	63
202	Increased risk of breast cancer in neurofibromatosis type 1: current insights. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 531-536.	1.0	31
203	Early development of infants with neurofibromatosis type 1: a case series. <i>Molecular Autism</i> , 2017, 8, 62.	2.6	48
204	Trunk neural crest cells: formation, migration and beyond. <i>International Journal of Developmental Biology</i> , 2017, 61, 5-15.	0.3	45
205	Neurofibromatosis type 2 service delivery in England. <i>Neurochirurgie</i> , 2018, 64, 375-380.	0.6	16
206	Neurofibromin ( <i>NF1</i> ) genetic variant structure-function analyses using a full-length mouse cDNA. <i>Human Mutation</i> , 2018, 39, 816-821.	1.1	15

#	ARTICLE	IF	CITATIONS
207	Worries and needs of adults and parents of adults with neurofibromatosis type 1. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 1150-1160.	0.7	32
208	Gorlin Syndrome. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 207-217.	0.2	4
209	JNK inhibitor CC-930 reduces fibrosis in a murine model of Nf1-deficient fracture repair. <i>Journal of Applied Biomedicine</i> , 2018, 16, 350-357.	0.6	1
211	SÃndrome de Gorlin. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 207-217.	0.2	19
212	The impact of a mindâ€‘body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis. <i>Journal of Neuro-Oncology</i> , 2018, 137, 321-329.	1.4	26
213	Editorial for â€œExperimental Approaches to Advance Therapies for Tumors of the Central and Peripheral Nervous Systemâ€• <i>Experimental Neurology</i> , 2018, 299, 267-269.	2.0	0
214	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844â€‘848. <i>American Journal of Human Genetics</i> , 2018, 102, 69-87.	2.6	144
215	Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 319-328.	1.1	16
216	Genomic Status of<i>MET</i>Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors. <i>Cancer Research</i> , 2018, 78, 3672-3687.	0.4	33
217	Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). <i>Molecular Autism</i> , 2018, 9, 12.	2.6	52
218	Microsurgery for patients diagnosed with neurofibromatosis type 2 complicated by vestibular schwannomas. <i>Medicine (United States)</i> , 2018, 97, e0270.	0.4	6
219	Clinical and molecular characterization of neurofibromatosis in southern Brazil. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 577-586.	1.5	3
220	Challenges associated with parenting youth with neurofibromatosis: A qualitative investigation. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 959-968.	0.7	8
221	Cutaneous neurofibromas in the genomics era: current understanding and open questions. <i>British Journal of Cancer</i> , 2018, 118, 1539-1548.	2.9	29
222	Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation. <i>Journal of Neuro-Oncology</i> , 2018, 138, 417-424.	1.4	14
223	A Xenograft Model of Vestibular Schwannoma and Hearing Loss. <i>Otology and Neurotology</i> , 2018, 39, e362-e369.	0.7	11
224	Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. <i>Archives of Disease in Childhood</i> , 2018, 103, 463-469.	1.0	23
225	Neurofibromatosis and Schwannomatosis. <i>Seminars in Neurology</i> , 2018, 38, 073-085.	0.5	53

#	ARTICLE	IF	CITATIONS
226	Human stem cell modeling in neurofibromatosis type 1 (NF1). <i>Experimental Neurology</i> , 2018, 299, 270-280.	2.0	20
227	Deficit in phonological processes: a characteristic of the neuropsychological profile of children with NF1. <i>Child Neuropsychology</i> , 2018, 24, 558-574.	0.8	25
228	RETINAL VASCULAR ABNORMALITIES IN A LARGE COHORT OF PATIENTS AFFECTED BY NEUROFIBROMATOSIS TYPE 1. <i>Retina</i> , 2018, 38, 585-593.	1.0	30
229	Orbital Imaging Manifestations of Neurocutaneous Syndromes Revisited. <i>Current Problems in Diagnostic Radiology</i> , 2018, 47, 61-67.	0.6	0
230	Impaired engagement of the ventral attention system in neurofibromatosis type 1. <i>Brain Imaging and Behavior</i> , 2018, 12, 499-508.	1.1	12
231	Unilateral vestibular schwannoma and meningiomas in a patient with <i>PIK3CA</i> -related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders. <i>Clinical Genetics</i> , 2018, 93, 187-190.	1.0	8
232	Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1). <i>Journal of Genetic Counseling</i> , 2018, 27, 115-123.	0.9	18
233	Prevalence of neurofibromatosis type 1 in the Finnish population. <i>Genetics in Medicine</i> , 2018, 20, 1082-1086.	1.1	89
234	Metaplastic spindle cell carcinoma of the breast in a patient with neurofibromatosis type 1. <i>Breast Journal</i> , 2018, 24, 391-394.	0.4	5
235	Neurological comorbidity in children with neurofibromatosis type 1. <i>Pediatrics International</i> , 2018, 60, 70-75.	0.2	25
236	Neurofibromatosis and Hydrocephalus. , 2018, , 1-16.		0
237	Neurofibromatosis type 1 as a model system to study molecular mechanisms of autism spectrum disorder symptoms. <i>Progress in Brain Research</i> , 2018, 241, 37-62.	0.9	14
238	Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas. <i>Eancermedicalsceince</i> , 2018, 12, 862.	0.6	11
239	Malignant peripheral nerve sheath tumours and neurofibromatosis 1: A case series and recommendations for care. <i>South African Journal of Oncology</i> , 2018, 2, .	0.1	0
240	Gene panel testing for breast cancer should not be used to confirm syndromic gene associations. <i>Npj Genomic Medicine</i> , 2018, 3, 32.	1.7	6
241	Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture. <i>EBioMedicine</i> , 2018, 36, 508-516.	2.7	1
242	Phenotypic expression of a spectrum of Neurofibromatosis Type 1 (NF1) mutations identified through NGS and MLPA. <i>Journal of the Neurological Sciences</i> , 2018, 395, 95-105.	0.3	29
243	Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. <i>BMC Health Services Research</i> , 2018, 18, 668.	0.9	19

#	ARTICLE	IF	CITATIONS
244	Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. <i>BMJ Open</i> , 2018, 8, e021800.	0.8	12
245	The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 919-932.	1.0	5
246	Parental age and risk of genetic syndromes predisposing to nervous system tumors: nested case&ndash;control study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 729-738.	1.5	5
247	Progressive bone impairment with age and pubertal development in neurofibromatosis type I. <i>Archives of Osteoporosis</i> , 2018, 13, 93.	1.0	25
248	NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 29.	2.3	42
249	Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient. <i>Neurosurgery</i> , 2018, 83, 38-42.	0.6	24
250	Imaging of cancer predisposition syndromes. <i>Pediatric Radiology</i> , 2018, 48, 1364-1375.	1.1	15
251	Update on Genetic Conditions Affecting the Skin and the Kidneys. <i>Frontiers in Pediatrics</i> , 2018, 6, 43.	0.9	7
252	Primary brain tumours in adults. <i>Lancet, The</i> , 2018, 392, 432-446.	6.3	882
253	Creating a comprehensive research strategy for cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S1-S4.	1.5	11
254	Neurofibromatosis type I: mutation spectrum of <i>NF1</i> in spanish patients. <i>Annals of Human Genetics</i> , 2018, 82, 425-436.	0.3	11
255	65 YEARS OF THE DOUBLE HELIX: Endocrine tumour syndromes in children and adolescents. <i>Endocrine-Related Cancer</i> , 2018, 25, T221-T244.	1.6	10
256	Medullary unidentified bright objects in Neurofibromatosis type 1: a case series. <i>BMC Pediatrics</i> , 2018, 18, 91.	0.7	16
257	A population&ndash;based cost&ndash;effectiveness study of early genetic testing in severe epilepsies of infancy. <i>Epilepsia</i> , 2018, 59, 1177-1187.	2.6	77
258	Cardiac Fibroma with Ventricular Tachycardia: An Unusual Clinical Presentation of Nevoid Basal Cell Carcinoma Syndrome. <i>Molecular Syndromology</i> , 2018, 9, 219-223.	0.3	8
259	Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis. <i>Neuropsychology Review</i> , 2018, 28, 317-340.	2.5	45
260	Genetic Evaluation of Common Neurocutaneous Syndromes. <i>Pediatric Neurology</i> , 2018, 89, 3-10.	1.0	14
261	Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease. <i>Neurosurgery</i> , 2018, 83, 1107-1118.	0.6	50

#	ARTICLE	IF	CITATIONS
262	Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. <i>Scientific Data</i> , 2018, 5, 180106.	2.4	20
263	Schwannomatosis: a genetic and epidemiological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1215-1219.	0.9	111
264	Sarcoma in neurofibromatosis 2: case report and review of the literature. <i>Familial Cancer</i> , 2019, 18, 97-100.	0.9	3
265	Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. <i>Clinical Genetics</i> , 2019, 96, 461-467.	1.0	16
266	Novel Statistical Analyses to Assess Hearing Outcomes After ABI Implantation in NF2 Patients: Systematic Review and Individualized Patient Data Analysis. <i>World Neurosurgery</i> , 2019, 128, e669-e682.	0.7	2
267	Neurofibromatosis and Hydrocephalus. , 2019, , 1107-1118.		0
268	Variation in Prevalence of Rare Heritable Traits – A Simulation Study – Illustrated by Neurofibromatosis Type 1. <i>Twin Research and Human Genetics</i> , 2019, 22, 229-232.	0.3	1
269	Long-Term Outcomes of Stereotactic Radiosurgery for Vestibular Schwannoma Associated with Neurofibromatosis Type 2 in Comparison to Sporadic Schwannoma. <i>Cancers</i> , 2019, 11, 1498.	1.7	20
270	Brain Tumors in NF1 Children: Influence on Neurocognitive and Behavioral Outcome. <i>Cancers</i> , 2019, 11, 1772.	1.7	10
271	Clinical Presentation and Novel Pathogenic Variants among 68 Chinese Neurofibromatosis 1 Children. <i>Genes</i> , 2019, 10, 847.	1.0	11
272	Isoform-specific NF1 mRNA levels correlate with disease severity in Neurofibromatosis type 1. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 261.	1.2	15
273	Evidence of small-fiber neuropathy in neurofibromatosis type 1. <i>Muscle and Nerve</i> , 2019, 60, 673-678.	1.0	9
274	The Diagnosis and Management of Neurofibromatosis Type 1. <i>Medical Clinics of North America</i> , 2019, 103, 1035-1054.	1.1	116
275	The Role of Merlin/NF2 Loss in Meningioma Biology. <i>Cancers</i> , 2019, 11, 1633.	1.7	44
277	Novel <i>SUFU</i> Frameshift Variant Leading to Meningioma in Three Generations in a Family with Gorlin Syndrome. <i>Case Reports in Genetics</i> , 2019, 2019, 1-5.	0.1	10
278	Ocular manifestations in Gorlin-Goltz syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 218.	1.2	17
279	Phakomatoses. <i>Dermatologic Clinics</i> , 2019, 37, 583-606.	1.0	8
280	Impact of Surgery on Long-Term Results of Hearing in Neurofibromatosis Type-2 Associated Vestibular Schwannomas. <i>Cancers</i> , 2019, 11, 1376.	1.7	15



#	ARTICLE	IF	CITATIONS
281	<p>Maternal smoking during pregnancy and risk of phacomatoses: results from a Swedish register-based study</p>. Clinical Epidemiology, 2019, Volume 11, 793-800.	1.5	2
282	Synchronous Development of Multicentric Malignant Peripheral Nerve Sheath Tumors: Institutional Review. World Neurosurgery, 2019, 124, e312-e314.	0.7	1
283	Successful Surgical Reconstruction of a Ruptured Brachial Artery Aneurysm in a Patient With Type 1 Neurofibromatosis. EJVES Short Reports, 2019, 43, 18-20.	0.7	4
284	Neurocutaneous Syndromes. , 2019, , 389-424.		0
285	Ocular alterations, molecular findings, and three novel pathological mutations in a series of NF2 patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1453-1458.	1.0	4
286	Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics, 2019, 143, .	1.0	115
287	Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool. Orphanet Journal of Rare Diseases, 2019, 14, 94.	1.2	14
288	Neurocutaneous Syndromes (Phakomatoses). , 2019, , 129-135.		0
290	Oral Signs of Genetic Disease. , 2019, , 227-252.		0
291	Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. Hereditary Cancer in Clinical Practice, 2019, 17, 12.	0.6	31
292	A novel PTCH1 mutation in basal cell nevus syndrome with rare craniofacial features. Human Genome Variation, 2019, 6, 16.	0.4	4
293	Clinical, radiological features and surgical strategies for 23 NF1 patients with intraorbital meningoencephalocele. Neurological Sciences, 2019, 40, 1217-1225.	0.9	5
294	Visuoperceptual Impairment in Children with NF1: From Early Visual Processing to Procedural Strategies. Behavioural Neurology, 2019, 2019, 1-10.	1.1	14
295	Isolated Pheochromocytoma in a 73-Year-Old Man With No Clinical Manifestations of Type 1 Neurofibromatosis Carrying an Unsuspected Deletion of the Entire NF1 Gene. Frontiers in Endocrinology, 2019, 10, 546.	1.5	5
296	Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of <i>Nf1</i>-Deficient Mice. Molecular Cancer Therapeutics, 2019, 18, 2321-2330.	1.9	10
298	Psychiatric disorders in patients with neurofibromatosis. Libri Oncologici, 2019, 46, 106-112.	0.1	2
299	Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study. BMJ Open, 2019, 9, e030601.	0.8	11
300	Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotypeâ€“Phenotype Correlations in a Large Independent Cohort. Cancers, 2019, 11, 1838.	1.7	19

#	ARTICLE	IF	CITATIONS
301	Caring for children with neurofibromatosis type 1. <i>Nursing</i> , 2019, 49, 30-36.	0.2	2
302	Long-term therapy with bevacizumab in a young patient affected by NF-2. <i>Anti-Cancer Drugs</i> , 2019, 30, 318-321.	0.7	2
303	[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma. <i>Otology and Neurotology</i> , 2019, 40, 826-835.	0.7	6
304	Successful step-by-step treatment of multiple tumours in neurofibromatosis type 2. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2019, 15, 101-105.	0.2	0
305	Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. <i>Journal of Medical Genetics</i> , 2019, 56, 53-62.	1.5	40
306	Patient Reported Outcomes Measurement Information System and Quality of Life in Neurological Disorders Measurement System to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma. <i>Journal of Pediatrics</i> , 2019, 206, 190-196.	0.9	19
307	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. <i>Familial Cancer</i> , 2019, 18, 281-284.	0.9	17
308	The molecular landscape of glioma in patients with Neurofibromatosis 1. <i>Nature Medicine</i> , 2019, 25, 176-187.	15.2	145
309	Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood. <i>Journal of Clinical Psychology in Medical Settings</i> , 2019, 26, 259-270.	0.8	10
310	First report of the efficacy of vestibular rehabilitation in improving function in patients with Neurofibromatosis type 2: an observational cohort study in a clinical setting. <i>Disability and Rehabilitation</i> , 2019, 41, 1632-1638.	0.9	2
311	Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. <i>Journal of Neuroscience Research</i> , 2019, 97, 45-56.	1.3	15
312	Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. <i>Skeletal Radiology</i> , 2020, 49, 199-219.	1.2	69
313	Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. <i>Genetics in Medicine</i> , 2020, 22, 53-59.	1.1	64
314	Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. <i>Genetics in Medicine</i> , 2020, 22, 398-406.	1.1	26
315	EANO guideline on the diagnosis and treatment of vestibular schwannoma. <i>Neuro-Oncology</i> , 2020, 22, 31-45.	0.6	190
316	Multifocal primary neuroblastoma tumor heterogeneity in siblings with co-occurring <i>PHOX2B</i> and <i>NF1</i> genetic aberrations. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 119-124.	1.5	6
317	Clinical spectrum of individuals with pathogenic <i>NF1</i> missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. <i>Human Mutation</i> , 2020, 41, 299-315.	1.1	80
318	Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, i117-i123.	0.4	3

#	ARTICLE	IF	CITATIONS
319	Retinal manifestations of the neurocutaneous disorders. <i>Current Opinion in Ophthalmology</i> , 2020, 31, 549-562.	1.3	1
320	Are morphological and structural MRI characteristics related to specific cognitive impairments in neurofibromatosis type 1 (NF1) children?. <i>European Journal of Paediatric Neurology</i> , 2020, 28, 89-100.	0.7	17
321	Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7559.	1.8	38
322	Gorlin's Goltz syndrome and epilepsy: A two-case report and review of the literature. <i>Epilepsy and Behavior Reports</i> , 2020, 14, 100384.	0.5	2
323	Virtual mind-body treatment for adolescents with neurofibromatosis: Study protocol for a single-blind randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2020, 95, 106078.	0.8	17
324	Inherited syndromes involving pancreatic neuroendocrine tumors. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 559-566.	0.6	19
325	Carcinogenesis as Side Effects of Iron and Oxygen Utilization: From the Unveiled Truth toward Ultimate Bioengineering. <i>Cancers</i> , 2020, 12, 3320.	1.7	22
326	Genodermatoses with malignant potential. <i>Clinics in Dermatology</i> , 2020, 38, 432-454.	0.8	9
327	Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas. <i>Scientific Reports</i> , 2020, 10, 12563.	1.6	16
328	Diagnosis of neurofibromatosis type 1 after rupture of aneurysm and consequent fatal hemothorax. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1543.e3-1543.e5.	0.7	3
329	Clinical and economic burden of neurofibromatosis type 2 in the United States. <i>Clinical Neurology and Neurosurgery</i> , 2020, 197, 106053.	0.6	2
330	Prediction and evaluation of deleterious and disease causing non-synonymous SNPs (nsSNPs) in human NF2 gene responsible for neurofibromatosis type 2 (NF2). <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 7044-7055.	2.0	9
331	Transition Readiness Assessment in Adolescents and Young Adults with Neurofibromatosis Type 1 (NF1). <i>Comprehensive Child and Adolescent Nursing</i> , 2023, 46, 223-239.	0.4	6
332	Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data. <i>Scientific Reports</i> , 2020, 10, 17857.	1.6	5
333	Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era. <i>Frontiers in Oncology</i> , 2020, 10, 566822.	1.3	17
334	The Role of Neuro-Ophthalmologists in the Care of Patients With Neurofibromatosis Type 2. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, S51-S56.	0.4	4
335	Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1. <i>Cancers</i> , 2020, 12, 2416.	1.7	7
336	Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma. <i>Frontiers in Neurology</i> , 2020, 11, 796.	1.1	16

#	ARTICLE	IF	CITATIONS
337	A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome. <i>Genome Research</i> , 2020, 30, 1170-1180.	2.4	4
338	Sporadic and Familial Variants in NF1: An Explanation of the Wide Variability in Neurocognitive Phenotype?. <i>Frontiers in Neurology</i> , 2020, 11, 368.	1.1	17
339	Biallelic NF1 inactivation in high grade serous ovarian cancers from patients with neurofibromatosis type 1. <i>Familial Cancer</i> , 2020, 19, 353-358.	0.9	3
340	The association of Neurofibromatosis Type 1 and lower urinary tract dysfunction in the paediatric population – A critical review of literature. <i>Journal of Pediatric Urology</i> , 2020, 16, 357-365.	0.6	6
341	Generation of two non-integrated induced pluripotent stem cell lines from urine-derived cells of a Chinese patient carrying NF1 gene mutation. <i>Stem Cell Research</i> , 2020, 46, 101842.	0.3	1
342	Contextualizing the Modern Epidemiology of Neurofibromatosis Type 2 in an Era of Heightened Detection of Sporadic Vestibular Schwannoma. <i>Otology and Neurotology</i> , 2020, 41, e501-e506.	0.7	6
343	Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. <i>Genetics in Medicine</i> , 2020, 22, 1794-1802.	1.1	7
344	Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2. <i>Otology and Neurotology</i> , 2020, 41, e529-e537.	0.7	13
345	Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality. <i>Child's Nervous System</i> , 2020, 36, 2471-2480.	0.6	7
346	Presenting symptoms in children with neurofibromatosis type 2. <i>Child's Nervous System</i> , 2020, 36, 2463-2470.	0.6	11
347	A Case of Non-Small-cell Lung Cancer in a Patient With Neurofibromatosis Type 1. <i>Clinical Lung Cancer</i> , 2020, 21, e261-e264.	1.1	0
348	Secondary Sarcomas: Biology, Presentation, and Clinical Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 463-474.	1.8	4
349	Neurocutaneous disorders. , 2020, , 1-26.		1
350	Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism. <i>Child's Nervous System</i> , 2020, 36, 2285-2295.	0.6	12
351	Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis – Practice Resource of the National Society of Genetic Counselors. <i>Journal of Genetic Counseling</i> , 2020, 29, 692-714.	0.9	13
352	Ante-natal counseling in phacomatoses. <i>Child's Nervous System</i> , 2020, 36, 2269-2277.	0.6	1
353	An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains. <i>Child's Nervous System</i> , 2020, 36, 2321-2332.	0.6	4
354	Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders. <i>Behavior Genetics</i> , 2020, 50, 191-202.	1.4	14

#	ARTICLE	IF	CITATIONS
355	<i>BRCA</i> and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes. <i>Radiographics</i> , 2020, 40, 306-325.	1.4	13
356	Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1. <i>Genes</i> , 2020, 11, 226.	1.0	11
357	A pediatric approach to management of skin growths in basal cell nevus syndrome. <i>Pediatric Dermatology</i> , 2020, 37, 527-530.	0.5	3
358	Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 245-249.	1.7	9
359	The Role of Dermal Fibroblasts in Nevoid Basal Cell Carcinoma Syndrome Patients: An Overview. <i>International Journal of Molecular Sciences</i> , 2020, 21, 720.	1.8	6
360	Perceived fatigue in children and young adults with neurofibromatosis type 1. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 878-883.	0.4	12
361	Diagnostic yield of a custom-designed multi-gene cancer panel in Irish patients with breast cancer. <i>Irish Journal of Medical Science</i> , 2020, 189, 849-864.	0.8	1
362	Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 37.	1.2	96
363	Molecular targets for NF1-associated malignant peripheral nerve sheath tumor. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 556-561.	0.3	1
364	High-frequency Basal Cell Carcinoma in Danish patients: prevalence and consistency. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e646-e648.	1.3	2
365	Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease. <i>Cancer Genetics</i> , 2020, 243, 1-6.	0.2	2
366	Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities. <i>Genes</i> , 2020, 11, 331.	1.0	9
367	Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts. <i>Annals of Oncology</i> , 2020, 31, 873-883.	0.6	35
368	NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. <i>Neuro-Oncology</i> , 2021, 23, 100-111.	0.6	27
369	Prevalence and risk factors for high-frequency basal cell carcinoma in the United States. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1493-1495.	0.6	2
370	Paragangliomas Throughout the Body: Hereditary Syndromes and Imaging Features Including 3D Cinematic Rendering. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 523-531.	0.6	0
371	Current Management of Large Vestibular Schwannomas for <sc>NF2</sc> Patients in a National Reference Center. <i>Laryngoscope</i> , 2021, 131, E98-E107.	1.1	7
372	Visible Distinctions and Congenital Anomalies of the Upper Extremities: Psychological Considerations. <i></i> , 2021, , 105-117.		0

#	ARTICLE	IF	CITATIONS
373	Cardiac Fibroma with Asymptomatic Ventricular Arrhythmia in an Adolescent with Gorlin's Syndrome. <i>Journal of Pediatric Genetics</i> , 0, , .	0.3	0
374	Autism Spectrum Disorder Symptom Profile Across the RASopathies. <i>Frontiers in Psychiatry</i> , 2020, 11, 585700.	1.3	9
375	Association between neurofibromatosis type 1 and cerebrovascular diseases in children: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0241096.	1.1	11
376	A Case of Neurofibromatosis Type 2 in Whom the Tumor was Preserved During a Cochlear Implant Surgery. <i>Practica Otologica</i> , 2021, 114, 575-579.	0.0	0
377	The recurrent plexiform neurofibroma of the scalp in neurofibromatosis type 1: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2021, 1, .	0.1	0
379	Reading Comprehension Impairment in Children With Neurofibromatosis Type 1 (NF1): The Need of Multimodal Assessment of Attention. <i>Journal of Child Neurology</i> , 2021, 36, 625-634.	0.7	3
380	Relevant Syndromes. , 2021, , 207-230.		0
381	Epidemiology of Genetic Diseases with Peripheral Nerve Tumors. , 2021, , 303-312.		0
382	Pheochromocytoma and Paraganglioma. , 2021, , 101-137.		0
383	Histopathology of Adult and Pediatric Glioblastoma. <i>Molecular Pathology Library</i> , 2021, , 67-89.	0.1	1
384	Corneal endothelial cells and central corneal thickness in patients with neurofibromatosis type 1. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 1522.	0.5	1
385	A Genome-First Approach to Characterize <i>DICER1</i> Pathogenic Variant Prevalence, Penetrance, and Phenotype. <i>JAMA Network Open</i> , 2021, 4, e210112.	2.8	25
386	Next-Generation Sequencing-Based Preimplantation Genetic Testing for De Novo NF1 Mutations. <i>Biochip Journal</i> , 2021, 15, 69-76.	2.5	3
387	Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas. <i>Current Otorhinolaryngology Reports</i> , 2021, 9, 170-176.	0.2	2
388	Contralateral Breast Cancer With Multiple Primary Neoplasms in a Patient With Neurofibromatosis Type 1: A Case Report and Review of the Literature. <i>Cureus</i> , 2021, 13, e13738.	0.2	0
389	Current concepts on ocular vascular abnormalities in the phakomatoses. <i>Seminars in Ophthalmology</i> , 2021, 36, 549-560.	0.8	1
390	Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. <i>JAMA Network Open</i> , 2021, 4, e210945.	2.8	66
391	A rare case of patient with neurofibromatosis type 1 in a genotype-phenotype correlation revealing a submicroscopic deletion on the long arm of chromosome 17. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2397-2399.	0.2	2

#	ARTICLE	IF	CITATIONS
392	Genotype-phenotype correlation in von Hippel-Lindau disease. <i>Acta Ophthalmologica</i> , 2021, 99, e1492-e1500.	0.6	14
393	Identifying challenges in neurofibromatosis: a modified Delphi procedure. <i>European Journal of Human Genetics</i> , 2021, 29, 1625-1633.	1.4	7
394	Molecular Characterization of Medulloblastoma in a Patient with Neurofibromatosis Type 1: Case Report and Literature Review. <i>Diagnostics</i> , 2021, 11, 647.	1.3	4
395	Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: a single-center study and literature review. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 180.	1.2	7
396	The first experience of using MEK inhibitors for type 1 neurofibromatosis in children in the Russian Federation in a hospital for short-term treatment at the National Medical Research Center. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2021, 8, 85-92.	0.1	1
397	MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions. <i>Biomarker Research</i> , 2021, 9, 26.	2.8	15
398	Exploring associations between constipation, severity of neurofibromatosis type 1 and NF1 mutational spectrum. <i>Scientific Reports</i> , 2021, 11, 9179.	1.6	1
399	Neurofibromatosis Type I: Case Reports of Two Novel Mutations. <i>Laboratory Medicine Online</i> , 2021, 11, 135-138.	0.0	0
400	Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). <i>Familial Cancer</i> , 2021, 20, 317-325.	0.9	22
401	Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. <i>Cell Death and Disease</i> , 2021, 12, 513.	2.7	5
402	What diagnosis is contributing to this man's spinal deformity?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2021, 34, 52-53.	0.1	0
403	The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. <i>Journal of Neurosurgery</i> , 2021, 134, 1419-1429.	0.9	23
404	Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review. <i>Adolescent Health, Medicine and Therapeutics</i> , 2021, Volume 12, 55-66.	0.7	8
405	Neurofibromatosis 2: new perspectives in treatment (case report). <i>Russian Journal of Neurosurgery</i> , 2021, 23, 109-118.	0.1	2
406	Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 1478-1494.	1.7	19
407	Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I. <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 22.	1.5	15
408	An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromas. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 239-246.	0.4	1
409	Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. <i>Journal of Neurosurgery</i> , 2021, 134, 1377-1385.	0.9	11

#	ARTICLE	IF	CITATIONS
410	Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5850.	1.8	87
411	Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review. <i>Neurological Sciences</i> , 2022, 43, 1281-1293.	0.9	7
413	WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. <i>Oncogene</i> , 2021, 40, 4229-4241.	2.6	7
414	A Rare Association Between Neurofibromatosis Type 1 and Thigh Leiomyosarcoma. <i>Journal of Clinical and Medical Research</i> , 0, , .	0.0	0
415	Three Arterial Ruptures in a Patient with Neurofibromatosis Type 1. <i>Annals of Vascular Diseases</i> , 2021, 14, 168-172.	0.2	4
416	Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. <i>Neurology</i> , 2021, 97, S91-S98.	1.5	19
417	Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics. <i>Cancers</i> , 2021, 13, 3870.	1.7	14
418	Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes. <i>Human Mutation</i> , 2021, 42, 1187-1207.	1.1	5
419	Iatrogenic ureteric stricture post image guided renal cryoablation in a patient with von hippel-lindau syndrome. <i>Radiology Case Reports</i> , 2021, 16, 1980-1984.	0.2	2
420	Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. <i>ESMO Open</i> , 2021, 6, 100223.	2.0	18
421	A guideline for the clinical management of basal cell naevus syndrome (Gorlinâ€“Goltz syndrome)*. <i>British Journal of Dermatology</i> , 2022, 186, 215-226.	1.4	19
422	Birth Characteristics Among Children Diagnosed with Neurofibromatosis Type 1 and Tuberous Sclerosis. <i>Journal of Pediatrics</i> , 2021, 239, 200-205.e2.	0.9	2
423	Predictors of cognitive, behavioural and academic difficulties in NF1. <i>Journal of Psychiatric Research</i> , 2021, 140, 545-550.	1.5	4
424	Development and preliminary evaluation of the Neurofibromatosis Type 1 Adult Quality of Life (NF1â€“AdQoL) questionnaire. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 271-281.	0.6	2
425	A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1â€“Related Plexiform Neurofibromas. <i>Annals of Pharmacotherapy</i> , 2022, 56, 716-726.	0.9	6
426	Lessons learned from drug trials in neurofibromatosis: A systematic review. <i>European Journal of Medical Genetics</i> , 2021, 64, 104281.	0.7	5
427	New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116340.	1.4	5
428	The mediating role of ADHD symptoms between executive function and social skills in children with neurofibromatosis type 1. <i>Child Neuropsychology</i> , 2022, 28, 318-336.	0.8	2



#	ARTICLE	IF	CITATIONS
429	Basal cell nevus syndrome: an update on clinical findings. <i>International Journal of Dermatology</i> , 2022, 61, 1047-1055.	0.5	7
430	The clinical application of single-sperm-based SNP haplotyping for PGT of patients with genetic diseases. <i>Reproductive BioMedicine Online</i> , 2021, , .	1.1	2
431	Malignant Peripheral Nerve Sheath Tumor Presenting as Horner's Syndrome. <i>Cureus</i> , 2021, 13, e18341.	0.2	1
432	Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. <i>Journal of Neuro-Oncology</i> , 2021, 154, 265-274.	1.4	3
433	Hydroxychloroquine induces matrix metalloproteinase 1 expression and apoptosis in neurofibromatosis type 1 Schwann cells. <i>Journal of Dermatological Science</i> , 2021, 104, 142-145.	1.0	0
434	RASopathies: The musculoskeletal consequences and their etiology and pathogenesis. <i>Bone</i> , 2021, 152, 116060.	1.4	12
435	Pediatric basal cell carcinoma burden and management preferences in Gorlin syndrome: A survey study. <i>JAAD International</i> , 2021, 5, 49-51.	1.1	3
436	Increased growth hormone secretion from lesions outside the anterior pituitary. , 2021, , 275-281.		0
437	Inherited Cancer Syndromes. , 2021, , 345-366.		0
438	Evaluation of peripheral nerve lesions. , 2021, , 104-117.		0
439	Approach to patients with the neoplasms associated with neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. , 2021, , 210-228.		0
440	Clinical Management of NF1 and Indications for Surgery. , 2021, , 347-354.		0
443	Molecular Biology of Basal and Squamous Cell Carcinomas. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1268, 171-191.	0.8	8
444	NF1 Germline and Somatic Mosaicism. , 2012, , 151-172.		1
445	Entrapment Neuropathies and Peripheral Nerve Tumors. , 2018, , 842-860.e3.		1
446	Clinical and neuroradiological characterisation of spinal lesions in adults with Neurofibromatosis type 1. <i>Journal of Clinical Neuroscience</i> , 2020, 77, 98-105.	0.8	11
447	Neurofibromatosis type 1 is not associated with subarachnoid haemorrhage. <i>PLoS ONE</i> , 2017, 12, e0178711.	1.1	10
448	VHL-Associated Optic Nerve Hemangioblastoma Treated with Stereotactic Radiosurgery. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 1-6.	0.2	6

#	ARTICLE	IF	CITATIONS
449	Von Hippel-Lindau disease: when neurosurgery meets nephrology, ophthalmology and genetics. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 548-565.	0.3	6
450	C2 neurofibromas in neurofibromatosis type 1: genetic and imaging characteristics. <i>Journal of Neurosurgery: Spine</i> , 2019, 30, 126-132.	0.9	8
451	The Neurofibromatoses. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2020, 117, 354-360.	0.6	32
452	Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome. <i>Annals of Maxillofacial Surgery</i> , 2015, 5, 14.	0.2	25
453	Metaplastic carcinoma of breast and neurofibromatosis 1: A rare association. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 374.	0.1	4
454	Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. <i>ELife</i> , 2014, 3, .	2.8	23
455	Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved. <i>Cureus</i> , 2019, 11, e5383.	0.2	8
456	Simultaneous robotic resection of pheochromocytoma and gastrointestinal stromal tumour in an adult neurofibromatosis type 1 patient: A single-docking procedure using da Vinci XI platform. <i>Journal of Minimal Access Surgery</i> , 2022, 18, 311.	0.4	1
457	Structural Abnormalities of the Central Retina in Neurofibromatosis Type 2. <i>Ophthalmic Research</i> , 2022, 65, 77-85.	1.0	1
458	Secretome analysis of human schwann cells derived from malignant peripheral nerve sheath tumor. <i>Proteomics</i> , 2022, 22, e2100063.	1.3	0
460	Novel Variants and Clinical Characteristics of 16 Patients from Southeast Asia with Genetic Variants in Neurofibromin-1. <i>Journal of Pediatric Genetics</i> , 0, , .	0.3	0
461	Proposed criteria for nevoid basal cell carcinoma syndrome in children assessed using statistical optimization. <i>Scientific Reports</i> , 2021, 11, 19791.	1.6	5
464	Mortality in Neurofibromatosis 1. , 2012, , 47-54.		2
465	Clinical study of 14 cases of nevoid basal cell carcinoma syndrome in 10 families. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2013, 59, 432-437.	0.0	2
466	HereditÄre Tumoren. , 2013, , 727-759.		0
467	Cranial Meningioma in Neurofibromatosis Type 2 Patients: Role of Mutations. <i>Tumors of the Central Nervous System</i> , 2014, , 271-276.	0.1	0
469	Mann med stort hode, lÄrrevansker og multiple basalcellekarsinomer. <i>Tidsskrift for Den Norske Lægeforening</i> , 2014, 134, 1151-1154.	0.2	0
470	Neurofibromatosis II. <i>Otorhinolaryngology Clinics</i> , 2014, 6, 4-6.	0.1	0

#	ARTICLE	IF	CITATIONS
471	Psychological Considerations: Visible Distinctions and Congenital Anomalies of the Upper Extremities. , 2015, , 73-82.		0
472	Pediatric Disorders: Viewpointâ€”Surgery. , 2015, , 415-426.		0
473	A case of pityriasis rosea of vidal accompanied by neurofibromatosis type 1. Nasza Dermatologia Online, 2015, 6, .	0.0	0
476	Epidemiology of Childhood Brain Tumors. , 2018, , 3-19.		0
478	High Grade Atrioventricular Block in Von Recklinghausen Disease: A Rare Phenomenon. Cardiology Research, 2018, 9, 176-179.	0.5	0
479	Synchronic Duodenal Gastrointestinal Stromal Tumor and Neuroendocrine Tumor in Association with Neurofibromatosis Type 1: A Case Report. Journal of Cancer Therapy, 2018, 09, 589-597.	0.1	0
481	Familial Syndromes. , 2018, , 1-55.		0
482	Von Hippelâ€”Lindau Disease, VHL. , 2018, , 1913-1913.		2
483	Familial Syndromes. , 2018, , 1-54.		0
485	A CASE OF PLEXIFORM NEUROFIBROMA WITH OCULAR MANIFESTATION. Journal of Evidence Based Medicine and Healthcare, 2018, 5, 931-933.	0.0	0
486	VON RECKLINGHAUSENâ€™S DISEASE WITH INTERSTITIAL LUNG DISEASE (ILD): A RARE ASSOCIATION. Journal of Evidence Based Medicine and Healthcare, 2018, 5, 3344-3347.	0.0	0
487	â€œTransforming the Beast to A Beautyâ€• Fifteen Years into the Making - Case Report of Congenital Neurofibromatosis. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 388-391.	0.1	0
488	Utility of MRI neurography in neurofibromatosis type I: Case example and review of MRI neurography literature. , 2019, 10, 12.		1
489	Angiomas Associated with Deafness, Blindness and Renal Carcinoma. , 2019, , 499-505.		0
490	A pathology mimicking dental abscess: facial plexiform neurofibroma. Acta Odontologica Turcica, 0, , 28-32.	0.1	0
491	Cuidado de niÃ±os con neurofibromatosis de tipo 1. Nursing (Ed EspaÃ±ola), 2019, 36, 26-31.	0.0	0
492	Cerebellar glioblastoma multiforme in an adult patient with neurofibromatosis type 1: an extremely rare report with review of literature. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2019, 55, .	0.4	0
493	Bilateral pheochromocytoma and a tumor of the jejunum with neurofibromatosis of type 1. Innovative Medicine of Kuban, 2019, , 55-61.	0.0	0

#	ARTICLE	IF	CITATIONS
494	Familial Syndromes. , 2020, , 1793-1834.		0
495	Von Hippel-Lindau syndrome and renal tumours: radiological diagnostic and treatment options. A case report and literature review. Acta Medica Lituanica, 2020, 27, 25-32.	0.2	0
496	The structure of neurofibromin isoform 2 reveals different functional states. Nature, 2021, 599, 315-319.	13.7	22
497	Multimodal image-guided ablation on management of renal cancer in Von-Hippel-Lindau syndrome patients from 2004 to 2021 at a specialist centre: A longitudinal observational study. European Journal of Surgical Oncology, 2022, 48, 672-679.	0.5	12
500	Treatment Analysis and Overall Survival Outcomes of Patients With Bilateral Vestibular Schwannoma. Otology and Neurotology, 2021, 42, 592-597.	0.7	5
501	Epidemiology of Neurofibromatosis Type 1. , 2020, , 1-4.		0
502	Tumors of the Cranial and Paraspinal Nerves. , 2020, , 205-225.		1
504	Neurofibromatosis type 1. , 2020, , 185-200.		1
507	Multiple Inherited Schwannomas, Meningiomas, and Ependymomas Syndrome in an Adult Patient. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 266-268.	0.1	0
508	Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2. Journal of Neuro-Oncology, 2021, 155, 373-381.	1.4	1
509	A Review of Breast Cancer Risk Factors in Adolescents and Young Adults. Cancers, 2021, 13, 5552.	1.7	7
510	Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning. American Journal of Medical Genetics, Part A, 2022, 188, 488-497.	0.7	3
511	Neurofibromatosis Type 1 with the Development of Pheochromocytoma and Breast Cancer. Internal Medicine, 2020, 59, 1665-1669.	0.3	1
512	Neurofibromatozis Tip 1: Çocuk hastalarda Klinik ve Beyin MRG bulguları. Turkish Journal of Pediatric Disease, 0, , 1-6.	0.0	0
515	Profiling the Word Reading Abilities of School-Age Children with Neurofibromatosis Type 1. Journal of the International Neuropsychological Society, 2021, 27, 484-496.	1.2	7
516	NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy. Current Gene Therapy, 2020, 20, 100-108.	0.9	8
517	Pigmented (melanotic) diffuse neurofibroma of the back in neurofibromatosis type 1. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2018, 7, Doc04.	0.1	0
519	Genetic predisposition in pediatric oncology. Medicine and Pharmacy Reports, 2020, 93, 323-334.	0.2	0



#	ARTICLE	IF	CITATIONS
542	Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Archives of Craniofacial Surgery, 2022, 23, 6-16.	0.4	2
543	Value of a café-au-lait macules screening clinic: Experience from The Hospital for Sick Children in Toronto. Pediatric Dermatology, 2022, , .	0.5	1
544	RAS and beyond: the many faces of the neurofibromatosis type 1 protein. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	11
545	Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service. British Journal of Cancer, 2022, 126, 1339-1345.	2.9	4
546	Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019. American Journal of Medical Genetics, Part A, 2022, 188, 1723-1727.	0.7	6
547	Managing Headache Disorders Associated with Tuberous Sclerosis and Neurofibromatosis. Current Pain and Headache Reports, 2022, 26, 281-288.	1.3	2
549	Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity. Journal of Clinical Oncology, 2022, , JCO2102385.	0.8	7
550	Atypical connectivity in the cortico-striatal network in NF1 children and its relationship with procedural perceptual-motor learning and motor skills. Journal of Neurodevelopmental Disorders, 2022, 14, 15.	1.5	1
551	Choroidal Abnormalities in Pediatric NF1: A Cohort Natural History Study. Cancers, 2022, 14, 1423.	1.7	3
552	Reviewing the occurrence of large genomic rearrangements in patients with inherited cancer predisposing syndromes: importance of a comprehensive molecular diagnosis. Expert Review of Molecular Diagnostics, 2022, 22, 319-346.	1.5	1
553	Nörofibromatozis Tip 1 Tanımlanmış Hastaların Klinik Özellikleri: Tek Merkez Deneyimi. Turkish Journal of Pediatric Disease, 0, , 1-5.	0.0	1
554	Old and new perspectives on Neurofibromatosis type 1: Clinical and molecular characterization of 832 patients from a single centre over 16 years. European Journal of Medical Genetics, 2022, 65, 104474.	0.7	0
555	Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification. Critical Reviews in Oncology/Hematology, 2022, 172, 103648.	2.0	8
557	Visual-processing deficits in children with neurofibromatosis type 1: A clinical marker of reading difficulties. European Journal of Paediatric Neurology, 2022, 38, 25-32.	0.7	4
558	Identification of NF1 Frameshift Variants in Two Chinese Families With Neurofibromatosis Type 1 and Early-Onset Hypertension. Frontiers in Pediatrics, 2021, 9, 785982.	0.9	2
561	Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1359-1366.	1.3	7
562	Sex- and age-related differences in autistic behaviours in children with neurofibromatosis type 1. Journal of Autism and Developmental Disorders, 2023, 53, 2835-2850.	1.7	2
563	Distinctive MicroRNA Profiles in Serum of Patients with Neurofibromatosis Type 2: A Bioinformatic Exploratory Study. World Neurosurgery, 2022, 164, e127-e133.	0.7	2

#	ARTICLE	IF	CITATIONS
564	Ganglioneuroblastoma in a Child With Neurofibromatosis Type 1: A Case Report and Literature Review. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, Publish Ahead of Print, .	0.3	1
566	Giant mediastinal mass in a 3-year-old boy: A rare presentation of neurofibromatosis type I. <i>Iranian Journal of Child Neurology</i> , 2021, 15, 109-113.	0.2	1
568	The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2022, 22, 70-78.	0.1	0
569	The Phakomatoses. , 2022, , 7891-7924.		0
570	Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2022, , .	0.6	2
571	Primary Benign Tumors of the Spinal Canal. <i>World Neurosurgery</i> , 2022, 164, 178-198.	0.7	8
572	Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1. <i>Frontiers in Surgery</i> , 2022, 9, 886697.	0.6	4
573	Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1. <i>Brain and Behavior</i> , 2022, 12, e2599.	1.0	5
574	Multidisciplinary integrated care pathway for von Hippelâ€“Lindau disease. <i>Cancer</i> , 2022, , .	2.0	7
575	Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. <i>Nature Communications</i> , 2022, 13, 2785.	5.8	29
576	A Case of Poorly Differentiated Synovial Sarcoma Arising in a Nasal Cavity Radiation Field: An Unusual Tumor in an Unusual Location. <i>International Journal of Surgical Pathology</i> , 2022, , 106689692210980.	0.4	1
577	Tumor and Constitutional Sequencing for Neurofibromatosis Type 1. <i>JCO Precision Oncology</i> , 2022, 6, e2100540.	1.5	4
578	Von Hippel Lindau Disease: A Review Article. , 2022, 16, 92-100.		0
579	Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. <i>Seminars in Cancer Biology</i> , 2022, 84, 228-241.	4.3	7
580	Case Report for Two Siblings Carrying Neurofibromatosis Type 1 with a Rare <i>c.5392C&gt;T</i> Mutation. <i>Balkan Journal of Medical Genetics</i> , 2021, 24, 99-102.	0.5	2
581	Neuroanatomical correlates of working memory performance in Neurofibromatosis 1. <i>Cerebral Cortex Communications</i> , 2022, 3, .	0.7	0
582	A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1. <i>Neurological Sciences</i> , 0, , .	0.9	0
583	Clinical characteristics and genetic testing outcome of suspected hereditary peripheral nerve sheath tumours in a tertiary cancer institution in Singapore. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, .	0.6	1

#	ARTICLE	IF	CITATIONS
584	Neurofibromatosis type 1: A comparison of the 1997 NIH and the 2021 revised diagnostic criteria in 75 children and adolescents. <i>Genetics in Medicine</i> , 2022, , .	1.1	1
585	Identifying Bone Matrix Impairments in a Mouse Model of Neurofibromatosis Type 1 (NF1) by Clinically Translatable Techniques. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1603-1621.	3.1	3
586	Diagnostic and follow-up protocol for adult patients with neurofibromatosis type 1 in a Spanish reference unit. <i>Revista Clínica Española</i> , 2022, , .	0.3	1
587	Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 2672-2683.	0.7	4
588	von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. <i>European Journal of Medical Genetics</i> , 2022, 65, 104538.	0.7	23
590	Multidisciplinary approach to Gorlin-Goltz syndrome: from diagnosis to surgical treatment of jawbones. <i>Maxillofacial Plastic and Reconstructive Surgery</i> , 2022, 44, .	0.7	6
591	Bibliometric analysis of the top 100 most-cited articles in neurofibromatosis. , 0, 13, 282.		2
592	Tumors of the nervous system. , 2023, , 203-228.		1
593	Steady-state visual evoked potentials in children with neurofibromatosis type 1: associations with behavioral rating scales and impact of psychostimulant medication. <i>Journal of Neurodevelopmental Disorders</i> , 2022, 14, .	1.5	5
595	Early Developmental Trajectories in Infants With Neurofibromatosis 1. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	3
596	The role of cardiologist in the multidisciplinary approach of Gorlin Syndrome: report of a case of supraventricular arrhythmias. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2022, 181, .	0.0	0
599	Early feasibility testing of a web-based mind-body resiliency program for adults with neurofibromatosis: The NF-Web study. <i>PEC Innovation</i> , 2022, 1, 100076.	0.3	2
601	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114742.	2.6	1
602	Scoliosis Secondary to Neurofibromatosis Type I Combined With Moyamoya Syndrome. <i>JBJS Case Connector</i> , 2022, 12, .	0.1	0
603	The mystery of brown shawl over back: a rare case of giant plexiform neurofibroma underlying a giant café-au-lait macule. <i>Pigment International</i> , 2022, 9, 131.	0.1	0
604	Mechanistic insights from animal models of neurofibromatosis type 1 cognitive impairment. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	4
605	Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 213-234.	1.8	13
606	Surgical management of skull base meningiomas and vestibular schwannomas. <i>Current Opinion in Oncology</i> , 2022, 34, 713-722.	1.1	3



#	ARTICLE	IF	CITATIONS
607	Genetics of Pancreatic Neuroendocrine Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 1033-1051.	0.9	3
608	Characterization of 22q12 Microdeletions Causing Position Effect in Rare NF2 Patients with Complex Phenotypes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10017.	1.8	0
609	The Evolving Role of Next-Generation Sequencing in Pediatric Neurosurgery: A Call for Action for Research, Clinical Practice, and Optimization of Care. <i>World Neurosurgery</i> , 2022, 168, 232-242.	0.7	1
610	A novel NF2 splicing mutant causes neurofibromatosis type 2 via liquid-liquid phase separation with large tumor suppressor and Hippo pathway. <i>IScience</i> , 2022, 25, 105275.	1.9	2
611	Genodermatoses – Opportunities for Early Detection and Cancer Prevention. <i>Current Genetic Medicine Reports</i> , 0, , .	1.9	0
612	Urologic Care of Children with Autism Spectrum Disorders or other Neurodevelopmental Disorders. <i>Autism and Child Psychopathology Series</i> , 2022, , 439-459.	0.1	0
613	COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis. <i>Genetics in Medicine</i> , 2023, 25, 100324.	1.1	1
614	Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
615	Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients. <i>Hormones</i> , 0, , .	0.9	4
616	Clinical and molecular features of neurofibromatosis types 1 and 2: a review of the literature. <i>Sarkomy Kosteji, MÅçgrih Tkanej I Opuholi KoÅ¾i</i> , 2022, 14, 33-41.	0.0	0
617	Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma. <i>Journal of Neurosurgery</i> , 2022, , 1-8.	0.9	2
618	Are neurofibromatosis type 1 (NF1) patients at increased risk of meningioma and in particular malignant meningioma?. <i>AME Case Reports</i> , 0, 6, 31-31.	0.2	0
619	Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype in vitro. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 493-505.	2.3	2
620	Neuroblastic tumors and neurofibromatosis type 1: A retrospective multicenter study in Italy and systematic review of the literature. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	1
621	Orthopaedic Manifestations of Neurofibromatosis Type I. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2022, 30, e1495-e1503.	1.1	0
622	Neurofibromatosis type 1: a clinical case. <i>Klinicheskaya Dermatologiya I Venerologiya</i> , 2022, 21, 758.	0.0	0
623	Assessment of Rare Genetic Variants to Identify Candidate Modifier Genes Underlying Neurological Manifestations in Neurofibromatosis 1 Patients. <i>Genes</i> , 2022, 13, 2218.	1.0	0
624	Clinical, radiographic, pathological and inherited characteristics of odontogenic keratocyst in nevoid basal cell carcinoma syndrome: a study in three Chilean families. <i>Oral Radiology</i> , 0, , .	0.9	0

#	ARTICLE	IF	CITATIONS
625	Characterization of health concerns in people with neurofibromatosis type 1. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2023, 11, .	0.6	5
626	Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study. <i>Oncology and Therapy</i> , 2023, 11, 97-110.	1.0	2
627	Challenges in Encapsulated Follicular-Patterned Tumors: How Much Is Enough? Evaluation of Nuclear Atypia, Architecture, and Invasion. <i>Surgical Pathology Clinics</i> , 2023, 16, 27-44.	0.7	1
629	A Translational Approach to Spinal Neurofibromatosis: Clinical and Molecular Insights from a Wide Italian Cohort. <i>Cancers</i> , 2023, 15, 59.	1.7	3
630	A preliminary study of the different memory systems in neurofibromatosis type 1: What is impaired and what is spared?. <i>Brain and Development</i> , 2023, , .	0.6	0
631	Differential rates of germline heterozygote and mosaic variants in <i>NF2</i> may show varying propensity for meiotic or mitotic mutation. <i>Journal of Medical Genetics</i> , 0, , jmg-2022-108960.	1.5	2
632	The Epidemiology of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 19-39.	0.8	3
633	Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis. <i>Diagnostics</i> , 2023, 13, 144.	1.3	3
635	Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 238-247.	0.9	2
636	Clinical characteristics, surgical management, and prognostic factors for supratentorial hemangioblastoma: A retrospective study. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
637	Genetic variants of cancer-associated genes analyzed using next-generation sequencing in small sporadic vestibular schwannomas. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
638	French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study. <i>European Journal of Medical Genetics</i> , 2023, 66, 104734.	0.7	0
639	Neurofibromatosis Type I and autism spectrum disorder caused by deletion of the NF1 gene: A case report. <i>Asian Journal of Psychiatry</i> , 2023, 84, 103544.	0.9	0
640	Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. <i>PLoS ONE</i> , 2023, 18, e0277305.	1.1	1
641	Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care. <i>Pediatric Health, Medicine and Therapeutics</i> , 0, Volume 14, 19-32.	0.7	4
642	Vitamin D and Bone Metabolism in Adult Patients with Neurofibromatosis Type 1. <i>Metabolites</i> , 2023, 13, 255.	1.3	2
643	Breast Cancer Screening Utilization and Outcomes in Women With Neurofibromatosis Type 1. <i>Clinical Breast Cancer</i> , 2023, 23, e200-e205.	1.1	2
644	When Neurofibromatosis Meets Diabetes: A Long-Term Follow-up in a Pediatric Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.3	0

#	ARTICLE	IF	CITATIONS
645	Neurofibromatosis Type 1: Pediatric Aspects and Review of Genotypeâ€“Phenotype Correlations. <i>Cancers</i> , 2023, 15, 1217.	1.7	5
646	The Perceived Influence of Neurofibromatosis Type 1(NF1) on the Parentsâ€™ Relationship. <i>Children</i> , 2023, 10, 448.	0.6	0
647	Management of Neurofibromatosis Type 2-Associated Vestibular Schwannomas. <i>Otolaryngologic Clinics of North America</i> , 2023, , .	0.5	1
648	Perspectives on the implications of carrying putative pathogenic variants in the medulloblastoma predisposition genes ELP1 and GPR161. <i>Familial Cancer</i> , 2023, 22, 341-344.	0.9	1
649	Strangled by His Nervesâ€”Cervical Plexiform Neurofibroma With Infantile Spinal Neurofibromatosis: Case Report in a 14 Years Old Child. <i>Clinical Medicine Insights: Case Reports</i> , 2023, 16, 117954762311643.	0.3	0
650	Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons. <i>Otolaryngologic Clinics of North America</i> , 2023, , .	0.5	0
651	Cost Analysis of Orthoptist-Led Neurofibromatosis Type 1 Screening Clinics. <i>British and Irish Orthoptic Journal</i> , 0, 19, .	0.1	0
653	Bone Mineral Density in Neurofibromatosis Type 1: A Systematic Review and Meta-Analysis. <i>Calcified Tissue International</i> , 2023, 113, 166-174.	1.5	1
667	Pediatric solid tumors. , 2023, , 427-477.		0
674	Brain and/or Spinal Cord Tumors Accompanied with Other Diseases or Syndromes. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 645-672.	0.8	1
699	Case report: Obstructive azoospermia as the first presentation of Von Hippel-Lindau disease. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
708	Miscellaneous Skeletal and Connective Tissue Disorders. , 2024, , 175-205.		0